Fakhro Mohammed, Ingemansson Richard, Algotsson Lars, Lindstedt Sandra
Department of Cardiothoracic Surgery, Skåne University Hospital, Lund University, Lund, Sweden.
Department of Thoracic Intensive Care and Anesthesia, Skåne University Hospital, Lund University, Lund, Sweden.
Ann Transplant. 2017 Sep 5;22:532-540. doi: 10.12659/aot.904819.
BACKGROUND Development of bronchiolitis obliterans syndrome (BOS) is a great limitation for patient survival in lung transplantation (LTx). A curative treatment for BOS is still missing, and in terminal stages re-transplantation (Re-LTx) is the only salvation. It is possible to slow the progress of BOS if it is detected at an early stage. This might be possible by assessing pulmonary function pattern. MATERIAL AND METHODS Between 1990 and 2014, 278 patients underwent LTx at Skåne University Hospital, Sweden. Pulmonary function was followed using spirometry (FEV1) and 6-minute walking test (6MWT) measured at 3, 6, and 12 months and annually. The endpoint used was freedom from BOS (BOS grade ≤1), BOS (BOS grade ≥2), and death or Re-LTx. RESULTS Double-lung transplantation (DLTx) showed a hazard ratio (HR) of 0.514 (p=0.001) versus recipients who underwent single-lung transplantation (SLTx). Regarding freedom from BOS, FEV1 showed an HR of 0.597 and 6MWT an HR of 0.982 (p<0.001). Regarding combined endpoint BOS ≥2 and Re-LTx, FEV1 showed an HR of 0.618 and 6MWT an HR of 0.972 (p<0.001). CONCLUSIONS Recipients with higher FEV1 or 6MWT values had better chances of survival. Recipients with DLTx had a significant survival benefit and a protective effect against development of BOS. As the distance that the patient can walk in 6 minutes increases, risk for death or Re-LTx is significantly lower, as is incidence of developing BOS grade ≥2. Understanding changes within pulmonary function are probably key to understanding patient prognosis.
背景 闭塞性细支气管炎综合征(BOS)的发展是肺移植(LTx)患者生存的重大限制。目前仍缺乏针对BOS的治愈性治疗方法,在终末期,再次移植(Re-LTx)是唯一的挽救方法。如果能在早期检测到BOS,就有可能减缓其进展。这可能通过评估肺功能模式来实现。
材料与方法 1990年至2014年期间,瑞典斯科讷大学医院有278例患者接受了肺移植。使用肺活量测定法(FEV1)和6分钟步行试验(6MWT)在3个月、6个月、12个月时以及每年对肺功能进行随访。所使用的终点指标为无BOS(BOS分级≤1)、BOS(BOS分级≥2)以及死亡或再次移植。
结果 与接受单肺移植(SLTx)的受者相比,双肺移植(DLTx)的风险比(HR)为0.514(p = 0.001)。关于无BOS,FEV1的HR为0.597,6MWT的HR为0.982(p < 0.001)。关于联合终点BOS≥2和再次移植,FEV1的HR为0.618,6MWT的HR为0.972(p < 0.001)。
结论 FEV1或6MWT值较高的受者有更好的生存机会。接受双肺移植的受者有显著的生存益处,并且对BOS的发展有保护作用。随着患者6分钟内步行距离的增加,死亡或再次移植的风险以及发生BOS分级≥2的发生率显著降低。了解肺功能的变化可能是理解患者预后的关键。